Charles River Laboratories (CRL) - Total Liabilities
Based on the latest financial reports, Charles River Laboratories (CRL) has total liabilities worth $4.06 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CRL cash flow metrics to assess how effectively this company generates cash.
Charles River Laboratories - Total Liabilities Trend (1998–2024)
This chart illustrates how Charles River Laboratories's total liabilities have evolved over time, based on quarterly financial data. Check CRL financial resilience to evaluate the company's liquid asset resilience ratio.
Charles River Laboratories Competitors by Total Liabilities
The table below lists competitors of Charles River Laboratories ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vienna Insurance Group AG
VI:VIG
|
Austria | €45.46 Billion |
|
Shenzhen Fastprint Circuit Tech Co Ltd
SHE:002436
|
China | CN¥9.14 Billion |
|
Western Alliance Bancorporation
NYSE:WAL
|
USA | $84.83 Billion |
|
Sunny Optical Technology (Group) Company Limited
F:SXC
|
Germany | €29.20 Billion |
|
Kiwoom
KO:039490
|
Korea | ₩65.89 Trillion |
|
Companhia Paranaense de Energia - COPEL
NYSE:ELPC
|
USA | $36.10 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥2.10 Billion |
|
Vibra Energia S.A.
SA:VBBR3
|
Brazil | R$39.65 Billion |
Liability Composition Analysis (1998–2024)
This chart breaks down Charles River Laboratories's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Charles River Laboratories worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.18 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Charles River Laboratories's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Charles River Laboratories (1998–2024)
The table below shows the annual total liabilities of Charles River Laboratories from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.02 Billion | -11.37% |
| 2023-12-31 | $4.54 Billion | -0.94% |
| 2022-12-31 | $4.58 Billion | +3.32% |
| 2021-12-31 | $4.43 Billion | +32.42% |
| 2020-12-31 | $3.35 Billion | +10.60% |
| 2019-12-31 | $3.03 Billion | +20.21% |
| 2018-12-31 | $2.52 Billion | +34.93% |
| 2017-12-31 | $1.87 Billion | +0.42% |
| 2016-12-31 | $1.86 Billion | +42.60% |
| 2015-12-31 | $1.30 Billion | +10.34% |
| 2014-12-31 | $1.18 Billion | +20.50% |
| 2013-12-31 | $979.96 Million | -0.32% |
| 2012-12-31 | $983.14 Million | -4.47% |
| 2011-12-31 | $1.03 Billion | -1.48% |
| 2010-12-31 | $1.04 Billion | +25.82% |
| 2009-12-31 | $830.27 Million | -13.56% |
| 2008-12-31 | $960.47 Million | +2.01% |
| 2007-12-31 | $941.57 Million | -1.21% |
| 2006-12-31 | $953.11 Million | +35.87% |
| 2005-12-31 | $701.48 Million | -38.71% |
| 2004-12-31 | $1.14 Billion | +252.43% |
| 2003-12-31 | $324.75 Million | -0.20% |
| 2002-12-31 | $325.40 Million | +21.03% |
| 2001-12-31 | $268.86 Million | -4.10% |
| 2000-12-31 | $280.35 Million | -40.72% |
| 1999-12-31 | $472.89 Million | +619.90% |
| 1998-12-31 | $65.69 Million | -- |
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells roden… Read more